Anti-angiogenic peptides application in cancer therapy; a review

Cancer is a disease advanced via surplus angiogenesis. The development of new anti-angiogenic therapeutic agents with more efficacy and fewer side effects is still quite necessary. Conventional therapies saving the life of many cancer patients but due to drug resistance and lack of specificity utili...

Full description

Saved in:
Bibliographic Details
Published in:Research in pharmaceutical sciences 2021-12, Vol.16 (6), p.559-574
Main Authors: Shoari, Alireza, Khodabakhsh, Farnaz, Ahangari Cohan, Reza, Salimian, Morteza, Karami, Elmira
Format: Article
Language:English
Subjects:
angiogenesis
cancer
nanobodies
natural resource
peptide
phage display
Antimitotic agents
Antineoplastic agents
Biological products
Chemical properties
Health aspects
Neovascularization
Peptides
Pharmaceutical research
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c593n-b4382ced7b4c96c02105481c29ff8c94ad51c750fc5a11d7101800de2991790b3
cites cdi_FETCH-LOGICAL-c593n-b4382ced7b4c96c02105481c29ff8c94ad51c750fc5a11d7101800de2991790b3
container_end_page 574
container_issue 6
container_start_page 559
container_title Research in pharmaceutical sciences
container_volume 16
creator Shoari, Alireza
Khodabakhsh, Farnaz
Ahangari Cohan, Reza
Salimian, Morteza
Karami, Elmira
description Cancer is a disease advanced via surplus angiogenesis. The development of new anti-angiogenic therapeutic agents with more efficacy and fewer side effects is still quite necessary. Conventional therapies saving the life of many cancer patients but due to drug resistance and lack of specificity utilizing these methods is faced with limits. Recently, new therapeutic agents have been developed and used to treat cancers such as scaffold proteins, monoclonal antibodies, tyrosine kinase inhibitors, and peptides. In antiangiogenic drug development, anti-angiogenic peptides design is a significant aim. Peptides have developed as substantial therapeutics that are being carefully investigated in angiogenesis-dependent diseases because of their high penetrating rate into the cancer cells, high specificity, and low toxicity. In this review, we focus on anti-angiogenic peptides in the field of cancer therapy that are designed, screened, or derived from nanobodies, mimotopes, phage displays, and natural resources.
doi_str_mv 10.4103/1735-5362.327503
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7766251dadd54427a21ec1b2657386f0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A680079766</galeid><doaj_id>oai_doaj_org_article_7766251dadd54427a21ec1b2657386f0</doaj_id><sourcerecordid>A680079766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c593n-b4382ced7b4c96c02105481c29ff8c94ad51c750fc5a11d7101800de2991790b3</originalsourceid><addsrcrecordid>eNptkk1r3DAQhk1paUKae0_F0LO3-rQsCqVLaJNAoJf2LOTR2FHilYzsZMm_jzZOQwyRDpJG7zya4VVRfKZkIyjh36jispK8ZhvOlCT8XXH8FNKCivfP-8P1UXE6TTckD6GZ0uxjccSFqvNZHhc_t2H2lQ29jz0GD-WI4-wdTqUdx8GDnX0MpQ8l2ACYyvkakx0fvpe2THjvcf-p-NDZYcLT5_Wk-Pf719-zi-rqz_nl2faqAql5qFrBGwboVCtA10AYJVI0FJjuuga0sE5SyF10IC2lTlFCG0IcMq2p0qTlJ8XlwnXR3pgx-Z1NDyZab54CMfXGptnDgEapumaSOuucFIIpyygCbVktFW_qjmTWj4U13rU7dIBhTnZYQdc3wV-bPt6bRtZMEJ0BXxdAb_N7PnQxy2DnJzDbOtetdC4hqzZvqPJ0uPMQA3Y-x1cJZEmAFKcpYfdSEiXm4Lk5mGoOpprF85zy5XUrLwn_Hc6C80Wwj8OMabod7vaYTNbehrhfgatXYCOlNqu_wR8BJha7WQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Anti-angiogenic peptides application in cancer therapy; a review</title><source>Open Access: PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Shoari, Alireza ; Khodabakhsh, Farnaz ; Ahangari Cohan, Reza ; Salimian, Morteza ; Karami, Elmira</creator><creatorcontrib>Shoari, Alireza ; Khodabakhsh, Farnaz ; Ahangari Cohan, Reza ; Salimian, Morteza ; Karami, Elmira</creatorcontrib><description>Cancer is a disease advanced via surplus angiogenesis. The development of new anti-angiogenic therapeutic agents with more efficacy and fewer side effects is still quite necessary. Conventional therapies saving the life of many cancer patients but due to drug resistance and lack of specificity utilizing these methods is faced with limits. Recently, new therapeutic agents have been developed and used to treat cancers such as scaffold proteins, monoclonal antibodies, tyrosine kinase inhibitors, and peptides. In antiangiogenic drug development, anti-angiogenic peptides design is a significant aim. Peptides have developed as substantial therapeutics that are being carefully investigated in angiogenesis-dependent diseases because of their high penetrating rate into the cancer cells, high specificity, and low toxicity. In this review, we focus on anti-angiogenic peptides in the field of cancer therapy that are designed, screened, or derived from nanobodies, mimotopes, phage displays, and natural resources.</description><identifier>ISSN: 1735-5362</identifier><identifier>EISSN: 1735-9414</identifier><identifier>DOI: 10.4103/1735-5362.327503</identifier><identifier>PMID: 34760005</identifier><language>eng</language><publisher>Iran: Wolters Kluwer - Medknow Publications</publisher><subject>angiogenesis; cancer; nanobodies; natural resource; peptide; phage display ; Antimitotic agents ; Antineoplastic agents ; Biological products ; Chemical properties ; Health aspects ; Neovascularization ; Peptides ; Pharmaceutical research ; Review</subject><ispartof>Research in pharmaceutical sciences, 2021-12, Vol.16 (6), p.559-574</ispartof><rights>Copyright: © 2021 Research in Pharmaceutical Sciences.</rights><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright: © 2021 Research in Pharmaceutical Sciences 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c593n-b4382ced7b4c96c02105481c29ff8c94ad51c750fc5a11d7101800de2991790b3</citedby><cites>FETCH-LOGICAL-c593n-b4382ced7b4c96c02105481c29ff8c94ad51c750fc5a11d7101800de2991790b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562409/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562409/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34760005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shoari, Alireza</creatorcontrib><creatorcontrib>Khodabakhsh, Farnaz</creatorcontrib><creatorcontrib>Ahangari Cohan, Reza</creatorcontrib><creatorcontrib>Salimian, Morteza</creatorcontrib><creatorcontrib>Karami, Elmira</creatorcontrib><title>Anti-angiogenic peptides application in cancer therapy; a review</title><title>Research in pharmaceutical sciences</title><addtitle>Res Pharm Sci</addtitle><description>Cancer is a disease advanced via surplus angiogenesis. The development of new anti-angiogenic therapeutic agents with more efficacy and fewer side effects is still quite necessary. Conventional therapies saving the life of many cancer patients but due to drug resistance and lack of specificity utilizing these methods is faced with limits. Recently, new therapeutic agents have been developed and used to treat cancers such as scaffold proteins, monoclonal antibodies, tyrosine kinase inhibitors, and peptides. In antiangiogenic drug development, anti-angiogenic peptides design is a significant aim. Peptides have developed as substantial therapeutics that are being carefully investigated in angiogenesis-dependent diseases because of their high penetrating rate into the cancer cells, high specificity, and low toxicity. In this review, we focus on anti-angiogenic peptides in the field of cancer therapy that are designed, screened, or derived from nanobodies, mimotopes, phage displays, and natural resources.</description><subject>angiogenesis; cancer; nanobodies; natural resource; peptide; phage display</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Biological products</subject><subject>Chemical properties</subject><subject>Health aspects</subject><subject>Neovascularization</subject><subject>Peptides</subject><subject>Pharmaceutical research</subject><subject>Review</subject><issn>1735-5362</issn><issn>1735-9414</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptkk1r3DAQhk1paUKae0_F0LO3-rQsCqVLaJNAoJf2LOTR2FHilYzsZMm_jzZOQwyRDpJG7zya4VVRfKZkIyjh36jispK8ZhvOlCT8XXH8FNKCivfP-8P1UXE6TTckD6GZ0uxjccSFqvNZHhc_t2H2lQ29jz0GD-WI4-wdTqUdx8GDnX0MpQ8l2ACYyvkakx0fvpe2THjvcf-p-NDZYcLT5_Wk-Pf719-zi-rqz_nl2faqAql5qFrBGwboVCtA10AYJVI0FJjuuga0sE5SyF10IC2lTlFCG0IcMq2p0qTlJ8XlwnXR3pgx-Z1NDyZab54CMfXGptnDgEapumaSOuucFIIpyygCbVktFW_qjmTWj4U13rU7dIBhTnZYQdc3wV-bPt6bRtZMEJ0BXxdAb_N7PnQxy2DnJzDbOtetdC4hqzZvqPJ0uPMQA3Y-x1cJZEmAFKcpYfdSEiXm4Lk5mGoOpprF85zy5XUrLwn_Hc6C80Wwj8OMabod7vaYTNbehrhfgatXYCOlNqu_wR8BJha7WQ</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Shoari, Alireza</creator><creator>Khodabakhsh, Farnaz</creator><creator>Ahangari Cohan, Reza</creator><creator>Salimian, Morteza</creator><creator>Karami, Elmira</creator><general>Wolters Kluwer - Medknow Publications</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Wolters Kluwer - Medknow</general><general>Wolters Kluwer Medknow Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211201</creationdate><title>Anti-angiogenic peptides application in cancer therapy; a review</title><author>Shoari, Alireza ; Khodabakhsh, Farnaz ; Ahangari Cohan, Reza ; Salimian, Morteza ; Karami, Elmira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c593n-b4382ced7b4c96c02105481c29ff8c94ad51c750fc5a11d7101800de2991790b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>angiogenesis; cancer; nanobodies; natural resource; peptide; phage display</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Biological products</topic><topic>Chemical properties</topic><topic>Health aspects</topic><topic>Neovascularization</topic><topic>Peptides</topic><topic>Pharmaceutical research</topic><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shoari, Alireza</creatorcontrib><creatorcontrib>Khodabakhsh, Farnaz</creatorcontrib><creatorcontrib>Ahangari Cohan, Reza</creatorcontrib><creatorcontrib>Salimian, Morteza</creatorcontrib><creatorcontrib>Karami, Elmira</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Research in pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shoari, Alireza</au><au>Khodabakhsh, Farnaz</au><au>Ahangari Cohan, Reza</au><au>Salimian, Morteza</au><au>Karami, Elmira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-angiogenic peptides application in cancer therapy; a review</atitle><jtitle>Research in pharmaceutical sciences</jtitle><addtitle>Res Pharm Sci</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>16</volume><issue>6</issue><spage>559</spage><epage>574</epage><pages>559-574</pages><issn>1735-5362</issn><eissn>1735-9414</eissn><abstract>Cancer is a disease advanced via surplus angiogenesis. The development of new anti-angiogenic therapeutic agents with more efficacy and fewer side effects is still quite necessary. Conventional therapies saving the life of many cancer patients but due to drug resistance and lack of specificity utilizing these methods is faced with limits. Recently, new therapeutic agents have been developed and used to treat cancers such as scaffold proteins, monoclonal antibodies, tyrosine kinase inhibitors, and peptides. In antiangiogenic drug development, anti-angiogenic peptides design is a significant aim. Peptides have developed as substantial therapeutics that are being carefully investigated in angiogenesis-dependent diseases because of their high penetrating rate into the cancer cells, high specificity, and low toxicity. In this review, we focus on anti-angiogenic peptides in the field of cancer therapy that are designed, screened, or derived from nanobodies, mimotopes, phage displays, and natural resources.</abstract><cop>Iran</cop><pub>Wolters Kluwer - Medknow Publications</pub><pmid>34760005</pmid><doi>10.4103/1735-5362.327503</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1735-5362
ispartof Research in pharmaceutical sciences, 2021-12, Vol.16 (6), p.559-574
issn 1735-5362
1735-9414
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7766251dadd54427a21ec1b2657386f0
source Open Access: PubMed Central; EZB Electronic Journals Library
subjects angiogenesis
cancer
nanobodies
natural resource
peptide
phage display
Antimitotic agents
Antineoplastic agents
Biological products
Chemical properties
Health aspects
Neovascularization
Peptides
Pharmaceutical research
Review
title Anti-angiogenic peptides application in cancer therapy; a review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A50%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-angiogenic%20peptides%20application%20in%20cancer%20therapy;%20a%20review&rft.jtitle=Research%20in%20pharmaceutical%20sciences&rft.au=Shoari,%20Alireza&rft.date=2021-12-01&rft.volume=16&rft.issue=6&rft.spage=559&rft.epage=574&rft.pages=559-574&rft.issn=1735-5362&rft.eissn=1735-9414&rft_id=info:doi/10.4103/1735-5362.327503&rft_dat=%3Cgale_doaj_%3EA680079766%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c593n-b4382ced7b4c96c02105481c29ff8c94ad51c750fc5a11d7101800de2991790b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/34760005&rft_galeid=A680079766&rfr_iscdi=true